SPRB Stock Forecast: Spruce Biosciences, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$41

The median 12-month analyst price target for Spruce Biosciences, Inc. is $143. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 10 of 100 as at 18 Nov 2026 — in the weakest quartile.

Market cap
$116.4M
Ticker Nerd rank
10/ 100
Median analyst target
$143
Analysts covering
9
Revenue$0.0
Operating income−$16.5M
Net income−$16.2M
Free cash flow−$22.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Spruce Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
10/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
49
Accruals
48
Volatility
28
Value
28
Revisions
20
Quality
19
Momentum
17
Issuance
7

Growth (49): Sales and profits are climbing, and climbing faster than before.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SPRB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPRB, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says9 analysts
9
Buy
0
Hold
0
Sell
$104
Low
$143
Median
$230
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Sept 2026CitizensReiteratesMarket Outperform$144
17 Sept 2026Lake StreetInitiatesBuy$149
17 Aug 2026GuggenheimMaintainsBuy$123 → $104
13 Aug 2026CitizensMaintainsMarket Outperform$150 → $144
13 July 2026B. Riley SecuritiesInitiatesBuy$160
16 June 2026GuggenheimInitiatesBuy—
9 June 2026Jones TradingInitiatesBuy—
1 June 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026CitizensMaintainsMarket Outperform—
27 Apr 2026Craig-HallumInitiatesBuy—
10 Mar 2026CitizensMaintainsMarket Outperform—
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Feb 2026HC Wainwright & Co.MaintainsBuy—
23 Dec 2025OppenheimerInitiatesOutperform—
22 Dec 2025HC Wainwright & Co.AssumesBuy$220
3 Dec 2025Leerink PartnersUpgradeOutperform—
11 Nov 2025CitizensMaintainsMarket Outperform—
28 Oct 2025JMP SecuritiesUpgradeMarket Outperform—
21 Oct 2025Leerink PartnersMaintainsMarket Perform—
16 Apr 2025RBC CapitalMaintainsSector Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SPRB.

Market Radar

This page is one stock. Monday covers all of them.

SPRB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

SPRB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
5
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.8×

Cheaper than 49% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−187.4%

Higher than 8% of US stocks

Return on assets
−54.2%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Spruce Biosciences, Inc. has a market value of $116.4M and an enterprise value of $37.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$51.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$42.8M.

  • Shares outstanding: 2.8M.

  • forward P/E: 10.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Spruce Biosciences, Inc. employs 25 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

SPRB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPRBSpruce Biosciences, Inc.$116.4M10
ARMPArmata Pharmaceuticals, Inc.$116.1M86
RTSNRetension Pharmaceuticals, Inc.$115.7M1
IMUXImmunic, Inc.$119.4M19
NTHINeOnc Technologies Holdings, Inc.$119.8M31
UPBUpstream Bio, Inc.$113.9M20
OKUROnKure Therapeutics, Inc.$113.9M52

Take a look at SPRB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Spruce Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SPRB

What is the SPRB stock price forecast for 2026-2027?

The median 12-month analyst price target for Spruce Biosciences, Inc. is $143, with estimates ranging from $104 to $230. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPRB stock a buy right now?

Of the 9 analysts covering Spruce Biosciences, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Spruce Biosciences, Inc. 10 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPRB?

As at 18 Nov 2026, Spruce Biosciences, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (49 of 100).

Will SPRB stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts is $143, and Ticker Nerd's factor model ranks Spruce Biosciences, Inc. 10 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPRB stock forecast for 2030?

No analyst covering Spruce Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $104 to $230 over the next 12 months.

What does Spruce Biosciences, Inc. do?

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare neurological and endocrine disorders with significant unmet medical need. Its current portfolio centers on enzyme replacement and small-molecule programs designed to address serious diseases where treatment options are limited or inadequate.

Company

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare neurological and endocrine disorders with significant unmet medical need. Its current portfolio centers on enzyme replacement and small-molecule programs designed to address serious diseases where treatment options are limited or inadequate. The company’s work includes therapies for conditions such as Sanfilippo Syndrome Type B and congenital adrenal hyperplasia, reflecting its emphasis on targeted medicines for underserved patient populations. Spruce Biosciences, Inc. operates in the biotechnology sector and participates in the broader rare-disease market, where specialized clinical development and regulatory expertise are essential to bringing therapies to patients. Headquartered in South San Francisco, California, the company is positioned as a development-stage biopharmaceutical business concentrated on advancing precision treatments for complex disorders.

CEO Dr. Javier Szwarcberg M.D., M.P.H. · 25 employees · United States · https://sprucebio.com